Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.77 |
| ▸ | NPC1 | O15118 | 5/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20550267 | 0.85 | ALDH1A1 (0.73) | RAB9ASMN1; SMN2ALDH1A1NPC1KMT2A | |
| SCHEMBL4154290 | 0.82 | RAB9A (0.70) | RAB9ASMN1; SMN2ALDH1A1NPC1KMT2A | |
| SCHEMBL20550692 | 0.82 | RAB9A (0.69) | RAB9ASMN1; SMN2ALDH1A1NPC1KMT2A | |
| SCHEMBL4161879 | 0.79 | ALDH1A1 (0.65) | RAB9ASMN1; SMN2ALDH1A1NPC1KMT2A | |
| SCHEMBL12278025 | 0.79 | ALDH1A1 (0.76) | RAB9ASMN1; SMN2ALDH1A1NPC1KMT2A | |
| SCHEMBL2412009 | 0.79 | ALDH1A1 (0.76) | RAB9ASMN1; SMN2ALDH1A1NPC1KMT2A | |
| SCHEMBL15655532 | 0.78 | RAB9A (0.72) | RAB9ASMN1; SMN2ALDH1A1NPC1KMT2A | |
| SCHEMBL12970049 | 0.78 | RAB9A (0.77) | RAB9ASMN1; SMN2ALDH1A1NPC1KMT2A | |
| SCHEMBL4167344 | 0.76 | ALDH1A1 (0.67) | RAB9ASMN1; SMN2ALDH1A1NPC1KMT2A | |
| SCHEMBL4170788 | 0.76 | ALDH1A1 (0.63) | RAB9ASMN1; SMN2ALDH1A1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414759-B2 | Phenylthiazoles and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414759-B2 | Phenylthiazoles and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180319784-A1 | PHENYLTHIAZOLES AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319784-A1 | PHENYLTHIAZOLES AND USES THEREOF | TPMT, TST, CLPP | RAB9A 4466/4885SMN1; SMN2 2885/4885ALDH1A1 2016/4885 |
| US-10414759-B2 | Phenylthiazoles and uses thereof | TPMT, TST, CLPP | RAB9A 4396/4885SMN1; SMN2 3041/4885ALDH1A1 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.